touchEXPERT OPINIONS Optimizing the management of gastroenteropancreatic neuroendocrine tumours
Watch leading experts explore how recent scientific and clinical advances may optimize the medical management of gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in 2021, and beyond.
Prof. Jonathan R Strosberg, who leads the NET Division at Moffitt Cancer Center, Tampa, FL, USA, summarizes the scientific and clinical evidence for GEP-NET treatment strategies in 2021.
1/3 Next InterviewIn this interview Prof. Strosberg answers the following questions:
- What is the current treatment landscape in GEP-NETs?
- How are advances in our understanding of the molecular pathology of GEP-NETs shaping future treatment prospects?
- What treatment options are on the horizon for GEP-NETs?
- How safe and effective are emerging treatment options in GEP-NETs?
Prof. Jonathan Strosberg is an Associate Professor at the Moffitt Cancer Center, specializing in the management of neuroendocrine malignancies. He is a graduate of Harvard University and Cornell University Medical College. He completed his fellowship at the Moffitt Cancer Center. He now leads the NET division at Moffitt and heads the GI department research programme. read more
Prof. Strosberg has published over 150 articles and book chapters on the diagnosis and management of neuroendocrine malignancies, including first-author publications in the New England Journal of Medicine, Journal of Clinical Oncology, Clinical Cancer Research, Annals of Oncology, Annals of Surgery, and Cancer. He has authored 12 articles for UptoDate. He is Vice Chair of the North American Neuroendocrine Tumor Society (NANETS), serves on the neuroendocrine guidelines committee of the National Comprehensive Cancer Network (NCCN) and on the neuroendocrine task force of the National Cancer Institute (NCI), and co-chairs the Neuroendocrine Tumor section of Southwest Oncology Group (SWOG).
Prof. Jonathan R Strosberg discloses: Consultancy fees from Novartis. Grants/research support fees from Novartis. Speaker fees from Ipsen.
Thorvardur R Halfdanarson, Professor of Oncology at the Mayo Clinic School of Medicine, Rochester, MN, USA, explores the potential impact of new data on clinical practice relevant to the management of GEP-NETs.
2/3 Next InterviewIn this interview Prof. Halfdanarson answers the following questions:
- Can we improve on the clinical outcomes achieved with current treatment approaches in GEP-NETS?
- What advances have been made in PRRT treatment for GEP-NETs?
- What are we learning from real-world experience surrounding clinical management of GEP-NETs?
- How do PRRT approaches compare with molecularly targeted therapies in terms of optimizing outcomes for patients with GEP-NETs?
- What more is needed to optimize outcomes for our patients with GEP-NETs, particularly in terms of survivorship and quality of life?
Thorvardur Halfdanarson is a Professor of Oncology at the Mayo Clinic College of Medicine and Science, and a Consultant in Medical Oncology at the Mayo Clinic, Rochester, USA, where he specializes in GI oncology with a focus on neuroendocrine tumours (NETs). Prof. Halfdanarson is the Chair of the GI Tumor Group within Medical Oncology at the Mayo Clinic, the Co-Chair of the Colorectal Cancer Tumor Board and the Assistant Hematology/Oncology Fellowship Director. read more
He is a member of the National Comprehensive Cancer Network (NCCN) guidelines panel for NETs, the past chair of the Guidelines and Publications Committee, is on the Board of Directors of the North American Neuroendocrine Tumor Society (NANETS), and is a faculty member for the European Society of Medical Oncology (ESMO) for neuroendocrine and endocrine neoplasms and cancers of unknown primary origin.
Prof. Thorvardur R Halfdanarson discloses: Advisory board/panel fees from Advanced Accelerator Applications, Crinetics Pharmaceuticals, Curium Pharma, Ipsen, ITM Isotopen Technologien München AG and Novartis. Grants/research support fees from Advanced Accelerator Applications and Novartis.
Diane Reidy-Lagunes, medical oncologist at the Memorial Sloan Kettering Cancer Center, New York, USA, appraises the need for a multidisciplinary approach to treatment and monitoring, and highlights the latest strategies for progressive disease management.
3/3 Take CE/CME TestIn this interview Dr Reidy-Lagunes answers the following questions:
- What requirements for multidisciplinary treatment and care are needed to optimize disease management?
- How should we monitor our patients with GEP-NETs to better support clinical and quality of life outcomes?
- How do we currently assess and define disease progression in GEP-NETS?
- How should we manage patients in the event of disease progression in the first-line setting?
- How might emerging treatment options impact clinical management following disease progression in future?
Dr Diane Reidy-Lagunes is a medical oncologist at the Memorial Sloan Kettering Cancer Center, New York, USA.
Dr Diane Reidy-Lagunes discloses: Advisory board/panel fees from Advanced Accelerator Applications, Chiasma Inc., ITM Isotopen Technologien München AG and OncoLogics. Grants/research support fees from Ipsen and Novartis.
Overview & Learning Objectives
Overview
In this activity, experts in the field of gastroenteropancreatic neuroendocrine tumours (GEP-NETs) explore how recent scientific and clinical advances may optimize approaches to the medical management of GEP-NETs in 2021, and beyond.
This activity is jointly provided by USF Health and touchIME. read more
Target Audience
This activity has been designed to meet the educational needs of oncologists, gastro-oncologists, gastroenterologists, radiologists and endocrinologists involved in the management of gastroenteropancreatic neuroendocrine tumours.
Disclosures
USF Health adheres to The Standards for Integrity and Independence in Accredited Continuing Education in all of its continuing professional development activities. It is USF Health’s policy that all persons in a position to influence content in this activity disclose any financial relationship with an ineligible organization. USF Health has mitigated all conflicts of interest.
Faculty
Prof. Jonathan R Strosberg discloses: Consultancy fees from Novartis. Grants/research support fees from Novartis. Speaker fees from Ipsen.
Prof. Thorvardur R Halfdanarson discloses: Advisory board/panel fees from Advanced Accelerator Applications, Crinetics Pharmaceuticals, Curium Pharma, Ipsen, ITM Isotopen Technologien München AG and Novartis. Grants/research support fees from Advanced Accelerator Applications and Novartis.
Dr Diane Reidy-Lagunes discloses: Advisory board/panel fees from Advanced Accelerator Applications, Chiasma Inc., ITM Isotopen Technologien München AG and OncoLogics. Grants/research support fees from Ipsen and Novartis.
Content reviewer
Olivia Pane, PharmD, CDCES has no financial interests/relationships or affiliations in relation to this activity.
Touch Medical Director
Paul Taylor has no financial interests/relationships or affiliations in relation to this activity.
USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
If you have questions regarding credit please contact cpdsupport@usf.eduÂ
Accreditations
Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.
USF Health designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu)
Advanced Practice Providers
Physician Assistants may claim a maximum of 0.75 Category 1 credit for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.
The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.
Date of original release: 12 August 2021. Date credits expire: 12 August 2022.
If you have any questions regarding credit please contact cpdsupport@usf.edu
Learning Objectives
After watching this activity, participants should be better able to:
- Interpret the data supporting new and emerging treatment options to improve outcomes for patients with GEP-NETs
- Analyse current guidelines for the therapeutic agents to treat GEP-NETs
- Appraise the criteria for assessing disease progression in GEP-NETs, and how they impact treatment choice
Register to touchONCOLOGY for FREE
- Peer reviewed journals and expert opinion
- Interactive CME and e-learning modules
- Video conference highlights
![](https://touchoncology.com/wp-content/uploads/sites/2/2021/04/Touch_Website-Image_Register-scaled.jpeg)